(Q34189242)

31 July 2017

1 reference

title

Technologies for the design, discovery, formulation and administration of vaccines (English)

1 reference

31 July 2017

1 reference

Ellis RW

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

19

1 reference

31 July 2017

issue

17-19

1 reference

31 July 2017

page(s)

2681-2687

1 reference

History of Sabin attenuated poliovirus oral live vaccine strains

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: technics for assay of effects of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Onset and Duration of Protective Immunity in Challenged Volunteers after Vaccination with Live Oral Cholera Vaccine CVD l03-HgR

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Use of zwitterionic detergent for the preparation of an influenza virus vaccine. 1: Preparation and characterization of disrupted virions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

An inactivated hepatitis A viral vaccine of cell culture origin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Immunogenicity of transgenic plant-derived hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Phase I Clinical Trial of a Recombinant Malaria Vaccine Consisting of the Circumsporozoite Repeat Region of Plasmodium Falciparum Coupled to Hepatitis B Surface Antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Direct gene transfer into mouse muscle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

DNA and RNA-based vaccines: principles, progress and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Gene transfer with a series of lipophilic DNA-binding molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Adjuvants--a classification and review of their modes of action

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Aluminum compounds used as adjuvants in vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Current options for vaccine delivery systems by mucosal routes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Immunization via hair follicles by topical application of naked DNA to normal skin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900504-1

7 January 2021

10.1016/S0264-410X(00)00504-1

Identifiers

DOI

1 reference

31 July 2017

1 reference